Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed by biopsy with breast cancer that is hormone receptor positive (meaning the cancer is fuelled by hormones like oestrogen or progesterone) and HER2 negative (a specific protein is not overactive on the cancer cells).
- People whose breast cancer is at an early stage — specifically stage I, II, or III, within certain size and spread categories (confirm with trial site for exact staging details).
- People who are planned to have surgery to remove the cancer with the goal of cure, and who have not yet received any treatment such as hormone therapy or chemotherapy before surgery.
- People who are willing to have small tissue samples (biopsies) taken from the tumour and nearby normal tissue during their surgery, for research purposes.
Who may not be able to join:
- People who are already enrolled in, or planning to join, another clinical trial that involves experimental treatments or procedures at the same time.
- People whose breast cancer is classified as triple negative (ER-/PR-/HER2-) or HER2 positive.
- People who currently have another active cancer diagnosis.
- People who could become pregnant and have not had a recent negative pregnancy test done as part of their standard cancer diagnosis and treatment preparation (outside of this trial).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Coral Omene, MD, PhD, Cancer Institute of New Jersey Rutgers
Phone: 732-235-3374
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measure glycolysis metabolism dependencies of hormone receptor positive/HER2 negative breast cancer using Liquid chromatography-mass spectrometry (LC-MS); Measure glycolysis metabolism dependencies of hormone receptor positive/HER2 negative breast cancer using Nuclear Magnetic Resonance (NMR) spectroscopy in parts per million (ppm).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.